Arch Biopartners Inc. (ARCH.V)
CAD 1.73
(-0.57%)
CAD 1.73
(-0.57%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -128.99 Thousand CAD | 74.35% |
| 2022 | -502.87 Thousand CAD | -235.72% |
| 2021 | -149.79 Thousand CAD | 92.94% |
| 2020 | -2.12 Million CAD | -51.26% |
| 2019 | -1.4 Million CAD | 6.6% |
| 2018 | -1.5 Million CAD | -145.98% |
| 2017 | -610.72 Thousand CAD | -48.29% |
| 2016 | -411.84 Thousand CAD | -19.19% |
| 2015 | -345.54 Thousand CAD | -96.3% |
| 2014 | -176.02 Thousand CAD | -288.11% |
| 2013 | -45.35 Thousand CAD | 0.0% |
| 2012 | - CAD | 0.0% |
| 2011 | - CAD | 0.0% |
| 2010 | - CAD | 0.0% |
| 2009 | - CAD | -100.0% |
| 2008 | 740.29 Thousand CAD | 31.29% |
| 2007 | 563.86 Thousand CAD | -11.85% |
| 2006 | 639.67 Thousand CAD | 28.14% |
| 2005 | 499.21 Thousand CAD | -55.78% |
| 2004 | 1.12 Million CAD | 21.06% |
| 2003 | 932.57 Thousand CAD | 61334.12% |
| 2002 | 1518.00 CAD | -10.97% |
| 2001 | 1705.00 CAD | -99.64% |
| 2000 | 471.06 Thousand CAD | 481.92% |
| 1999 | 80.95 Thousand CAD | -44.92% |
| 1998 | 146.97 Thousand CAD | 167.63% |
| 1997 | 54.91 Thousand CAD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 128.41 Thousand CAD | 104.38% |
| 2024 Q3 | -473.1 Thousand CAD | 0.0% |
| 2024 Q2 | - CAD | -100.0% |
| 2023 Q3 | -196.51 Thousand CAD | 68.92% |
| 2023 FY | -128.99 Thousand CAD | 74.35% |
| 2023 Q4 | -2.93 Million CAD | -1391.14% |
| 2023 Q2 | -632.29 Thousand CAD | -1829.13% |
| 2023 Q1 | -32.77 Thousand CAD | 96.6% |
| 2022 Q1 | 29.15 Thousand CAD | -96.68% |
| 2022 Q3 | -61.75 Thousand CAD | 75.02% |
| 2022 FY | -502.87 Thousand CAD | -235.72% |
| 2022 Q4 | -964.33 Thousand CAD | -1461.6% |
| 2022 Q2 | -247.21 Thousand CAD | -948.01% |
| 2021 Q2 | -809.33 Thousand CAD | 39.6% |
| 2021 FY | -149.79 Thousand CAD | 92.94% |
| 2021 Q4 | 878.69 Thousand CAD | -23.57% |
| 2021 Q3 | 1.14 Million CAD | 242.05% |
| 2021 Q1 | -1.34 Million CAD | -0.45% |
| 2020 Q3 | -338.77 Thousand CAD | -375.92% |
| 2020 Q1 | -580.07 Thousand CAD | -12.3% |
| 2020 FY | -2.12 Million CAD | -51.26% |
| 2020 Q4 | -1.33 Million CAD | -293.78% |
| 2020 Q2 | -71.18 Thousand CAD | 87.73% |
| 2019 Q4 | -516.54 Thousand CAD | -1023.61% |
| 2019 Q3 | -45.97 Thousand CAD | 82.87% |
| 2019 FY | -1.4 Million CAD | 6.6% |
| 2019 Q2 | -268.41 Thousand CAD | 62.89% |
| 2019 Q1 | -723.27 Thousand CAD | -42.29% |
| 2018 Q2 | -486.88 Thousand CAD | -87.47% |
| 2018 Q1 | -259.71 Thousand CAD | -36.24% |
| 2018 FY | -1.5 Million CAD | -145.98% |
| 2018 Q4 | -508.32 Thousand CAD | -105.48% |
| 2018 Q3 | -247.37 Thousand CAD | 49.19% |
| 2017 Q4 | -190.62 Thousand CAD | 11.54% |
| 2017 Q3 | -215.48 Thousand CAD | -604.49% |
| 2017 FY | -610.72 Thousand CAD | -48.29% |
| 2017 Q1 | -175.17 Thousand CAD | -28.93% |
| 2017 Q2 | -30.58 Thousand CAD | 82.54% |
| 2016 Q3 | -120.22 Thousand CAD | -48.64% |
| 2016 FY | -411.84 Thousand CAD | -19.19% |
| 2016 Q1 | -74.86 Thousand CAD | 50.85% |
| 2016 Q2 | -80.88 Thousand CAD | -8.03% |
| 2016 Q4 | -135.87 Thousand CAD | -13.02% |
| 2015 FY | -345.54 Thousand CAD | -96.3% |
| 2015 Q2 | -85.19 Thousand CAD | -66.02% |
| 2015 Q3 | -80.92 Thousand CAD | 5.01% |
| 2015 Q4 | -152.31 Thousand CAD | -88.22% |
| 2015 Q1 | -51.31 Thousand CAD | -2019.72% |
| 2014 Q1 | -36.78 Thousand CAD | -690.03% |
| 2014 Q2 | -36.55 Thousand CAD | 0.63% |
| 2014 Q4 | 2673.00 CAD | 103.21% |
| 2014 FY | -176.02 Thousand CAD | -288.11% |
| 2014 Q3 | -83.36 Thousand CAD | -128.07% |
| 2013 Q2 | -28.43 Thousand CAD | 0.0% |
| 2013 Q4 | -4656.00 CAD | -212.9% |
| 2013 Q1 | - CAD | 0.0% |
| 2013 Q3 | -1488.00 CAD | 94.77% |
| 2013 FY | -45.35 Thousand CAD | 0.0% |
| 2012 Q2 | - CAD | 0.0% |
| 2012 Q4 | - CAD | 0.0% |
| 2012 FY | - CAD | 0.0% |
| 2012 Q3 | - CAD | 0.0% |
| 2012 Q1 | - CAD | 0.0% |
| 2011 Q4 | - CAD | 0.0% |
| 2011 FY | - CAD | 0.0% |
| 2011 Q3 | - CAD | 0.0% |
| 2011 Q2 | - CAD | 0.0% |
| 2011 Q1 | - CAD | 0.0% |
| 2010 Q2 | - CAD | 0.0% |
| 2010 FY | - CAD | 0.0% |
| 2010 Q4 | - CAD | 0.0% |
| 2010 Q3 | - CAD | 0.0% |
| 2010 Q1 | - CAD | 0.0% |
| 2009 Q4 | - CAD | 0.0% |
| 2009 FY | - CAD | -100.0% |
| 2009 Q2 | 110.13 Thousand CAD | -43.79% |
| 2009 Q3 | - CAD | -100.0% |
| 2009 Q1 | 195.92 Thousand CAD | -34.04% |
| 2008 Q4 | 297.03 Thousand CAD | 90.16% |
| 2008 Q3 | 156.2 Thousand CAD | 71.4% |
| 2008 FY | 740.29 Thousand CAD | 31.29% |
| 2008 Q2 | 91.13 Thousand CAD | -56.65% |
| 2008 Q1 | 210.22 Thousand CAD | 65.49% |
| 2007 Q2 | 86.49 Thousand CAD | -76.22% |
| 2007 FY | 563.86 Thousand CAD | -11.85% |
| 2007 Q4 | 127.03 Thousand CAD | -9.34% |
| 2007 Q3 | 140.11 Thousand CAD | 61.99% |
| 2007 Q1 | 363.71 Thousand CAD | 339.22% |
| 2006 FY | 639.67 Thousand CAD | 28.14% |
| 2006 Q4 | 82.81 Thousand CAD | -45.7% |
| 2006 Q3 | 152.49 Thousand CAD | 275.09% |
| 2006 Q2 | 40.65 Thousand CAD | 143.55% |
| 2006 Q1 | -93.35 Thousand CAD | -122.17% |
| 2005 Q2 | 120.44 Thousand CAD | -68.35% |
| 2005 Q1 | 380.55 Thousand CAD | 261.83% |
| 2005 FY | 499.21 Thousand CAD | -55.78% |
| 2005 Q4 | 421.12 Thousand CAD | 725.77% |
| 2005 Q3 | 50.99 Thousand CAD | -57.66% |
| 2004 FY | 1.12 Million CAD | 21.06% |
| 2004 Q1 | - CAD | 0.0% |
| 2004 Q2 | 194.05 Thousand CAD | 0.0% |
| 2004 Q3 | 449.21 Thousand CAD | 131.49% |
| 2004 Q4 | 105.17 Thousand CAD | -76.59% |
| 2003 Q1 | -5609.00 CAD | 0.0% |
| 2003 FY | 932.57 Thousand CAD | 61334.12% |
| 2003 Q4 | - CAD | 0.0% |
| 2003 Q3 | - CAD | 0.0% |
| 2003 Q2 | - CAD | 100.0% |
| 2002 FY | 1518.00 CAD | -10.97% |
| 2002 Q3 | 10.78 Thousand CAD | 0.0% |
| 2002 Q4 | - CAD | -100.0% |
| 2002 Q1 | 199.00 CAD | 87.74% |
| 2002 Q2 | - CAD | -100.0% |
| 2001 Q4 | 106.00 CAD | -86.75% |
| 2001 Q3 | 800.00 CAD | 33.33% |
| 2001 Q2 | 600.00 CAD | -99.57% |
| 2001 Q1 | 138.07 Thousand CAD | 135.0% |
| 2001 FY | 1705.00 CAD | -99.64% |
| 2000 Q2 | 196.04 Thousand CAD | 293.73% |
| 2000 FY | 471.06 Thousand CAD | 481.92% |
| 2000 Q1 | 49.79 Thousand CAD | 4979000.0% |
| 2000 Q4 | 58.75 Thousand CAD | -24.85% |
| 2000 Q3 | 78.18 Thousand CAD | -60.12% |
| 1999 Q4 | 1.00 CAD | 0.0% |
| 1999 FY | 80.95 Thousand CAD | -44.92% |
| 1999 Q1 | 130.56 Thousand CAD | 3676.8% |
| 1999 Q2 | 1.00 CAD | -100.0% |
| 1999 Q3 | 1.00 CAD | 0.0% |
| 1998 FY | 146.97 Thousand CAD | 167.63% |
| 1998 Q4 | 3457.00 CAD | 71.48% |
| 1998 Q2 | 10.94 Thousand CAD | 0.0% |
| 1998 Q3 | 2016.00 CAD | -81.58% |
| 1997 FY | 54.91 Thousand CAD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Covalon Technologies Ltd. | 14.36 Million CAD | 100.898% |
| Hemostemix Inc. | -223.00 CAD | -57743.946% |
| Universal Ibogaine Inc. | 1.07 Million CAD | 112.046% |
| Kane Biotech Inc. | 109.47 Thousand CAD | 217.833% |
| MedMira Inc. | -434.91 Thousand CAD | 70.341% |
| Marvel Biosciences Corp. | -887.51 Thousand CAD | 85.466% |
| NervGen Pharma Corp. | -145 Thousand CAD | 11.042% |
| XORTX Therapeutics Inc. | -188.54 Thousand CAD | 31.585% |